{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-23-000017","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.188696+00:00","generated_at":"2026-06-17T22:52:13.049279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Exagen Q4 net loss $14.4M on $5.5M goodwill impairment; Q1 revenue guidance raised to $9.2-9.7M","bullets":["Record 135,210 AVISE CTD tests in 2022; 33,819 in Q4; cumulative ~750,000 since 2012 launch.","Q4 revenue $12.8M (+0.8% YoY); gross margin fell to 50.9% from 61.1% on inflation and mix.","Full-year 2022 net loss $47.4M vs $26.9M in 2021; operating expenses rose to $91.6M.","New CEO John Aballi joined Q4 2022; strategy focuses on reducing cash burn and reaching profitability.","Q1 2023 revenue guidance raised to $9.2-9.7M from prior $8.2-9.2M range."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-23-000017","json":"https://secwatch.observer/filing/0001274737-23-000017.json","markdown":"https://secwatch.observer/filing/0001274737-23-000017.md","text":"https://secwatch.observer/filing/0001274737-23-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000017/0001274737-23-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000017/exdx-20230320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:52:13.049279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b8ddbec80c7c706ec9c6da037ab0ffcd815b715","claim":"EXAGEN INC. reported the fourth quarter of 2022 results: revenue $12.8 million, net income $14.4 million. Guidance raised.","evidence_excerpt":"of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests. • Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022. • John Aballi, President and CEO, joined the Company in the fourth quarter of 2022 and implemented a new strategy focused on reducing cash burn","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000017/0001274737-23-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$12.8 million"},{"label":"Net income","value":"$14.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e628af03c4c83753bdd13cc9e983f42747b76694","claim":"EXAGEN INC. reported the year ended December 31, 2022 results: revenue $45.6 million, net income $47.4 million. Guidance raised.","evidence_excerpt":"including 33,819 tests for the fourth quarter of 2022. Since the launch of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests. • Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022. • John Aballi, President and CEO, joined the Company in the fourth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000017/0001274737-23-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$45.6 million"},{"label":"Net income","value":"$47.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}